Date: 2015-09-28
Type of information: Initiation of the trial
phase: 3
Announcement: initiation of the trial
Company: Celgene (USA - NJ)
Product: ozanimod - RPC1063
Action
mechanism: sphingosine 1-phosphate receptor (S1PR) modulator. Ozanimod is a small molecule sphingosine 1-phosphate 1 and 5 receptor modulator in development for immune-inflammatory indications including relapsing multiple sclerosis and inflammatory bowel disease. Treatment with S1P receptor modulators is believed to work by interfering with S1P signaling and blocks the response of lymphocytes to exit signals from the lymph nodes, sequestering them within the nodes. The result is thought to be a downward modulation of circulating lymphocytes and anti-inflammatory activity by inhibiting cell migration to sites of inflammation.
Disease: multiple sclerosis
Therapeutic area: Autoimmune diseases - Neurodegenerative diseases
Country: Belgium, Bulgaria, Georgia, Greece, Hungary, Poland, Romania, Russian Federation, Serbia, Spain, Ukraine, USA
Trial
details: The purpose of this open-label extension trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis. (NCT02576717)
Latest
news: The trial is an open label extension study. Eligible patients from the RPC01-201 and RPC01-301 trials diagnosed with relapsing multiple sclerosis will be enrolled to receive study drug until the end of the trial or until the Sponsor discontinues the development program.
